First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin

Inclusion Criteria: * Signed informed consent * Male or female subjects ≥ 18 years of age * ECOG PS (Eastern Cooperative Oncology Group Performance Status) of 0 or 1 * Patients with advanced malignant epithelioid mesothelioma or advanced recurrent serous ovarian cancer, who have exhausted available therapeutic options; in addition, in the dose expansion part of the study, patients with metastatic pancreatic adenocarcinoma, who have exhausted available therapeutic options * Availability of fresh or archival tumor tissue samples * Adequate bone marrow, liver and renal function, as assessed by pre-defined laboratory requirements (within 28 days before start of study drug treatment) * A negative serum pregnancy test in women of childbearing potential (WOCBP) performed within 7 days before the start of study drug administration. Women and men of reproductive potential must agree to use highly effective methods of contraception, when sexually active. Exclusion Criteria: * Impaired cardiac function, clinically significant cardiac disease or cardiac arrhythmias * Pericarditis (any CTCAE grade) or pericardial effusion (CTCAE Grade ≥ 2) * Left Ventricular Ejection Fraction (LVEF) \< 50% (as measured at screening by echocardiogram). * History of anaphylactic reactions to monoclonal antibody therapy * History of Myelodysplastic syndrome (MDS)/treatment-related acute myeloid leukemia (t-AML) or with features suggestive of MDS/AML * Infections of CTCAE (Common Terminology Criteria for A…